MX2023005895A - Tratamiento de la ansiedad al hablar en publico con un agonista del receptor nicotinico alfa 7 de la acetilcolina. - Google Patents

Tratamiento de la ansiedad al hablar en publico con un agonista del receptor nicotinico alfa 7 de la acetilcolina.

Info

Publication number
MX2023005895A
MX2023005895A MX2023005895A MX2023005895A MX2023005895A MX 2023005895 A MX2023005895 A MX 2023005895A MX 2023005895 A MX2023005895 A MX 2023005895A MX 2023005895 A MX2023005895 A MX 2023005895A MX 2023005895 A MX2023005895 A MX 2023005895A
Authority
MX
Mexico
Prior art keywords
treatment
alpha
receptor agonist
acetylcholine receptor
nicotinic acetylcholine
Prior art date
Application number
MX2023005895A
Other languages
English (en)
Spanish (es)
Inventor
Yunsheng He
Christos Polymeropoulos
Mihael Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2023005895A publication Critical patent/MX2023005895A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2023005895A 2020-11-25 2021-11-24 Tratamiento de la ansiedad al hablar en publico con un agonista del receptor nicotinico alfa 7 de la acetilcolina. MX2023005895A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063118121P 2020-11-25 2020-11-25
US202063118132P 2020-11-25 2020-11-25
US202163158449P 2021-03-09 2021-03-09
PCT/US2021/060720 WO2022115526A1 (en) 2020-11-25 2021-11-24 Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Publications (1)

Publication Number Publication Date
MX2023005895A true MX2023005895A (es) 2023-06-06

Family

ID=78957498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005895A MX2023005895A (es) 2020-11-25 2021-11-24 Tratamiento de la ansiedad al hablar en publico con un agonista del receptor nicotinico alfa 7 de la acetilcolina.

Country Status (8)

Country Link
US (1) US20230381169A1 (https=)
EP (1) EP4251158A1 (https=)
JP (1) JP2023553354A (https=)
KR (1) KR20230112622A (https=)
AU (1) AU2021387993A1 (https=)
CA (1) CA3199760A1 (https=)
MX (1) MX2023005895A (https=)
WO (1) WO2022115526A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily

Also Published As

Publication number Publication date
AU2021387993A9 (en) 2024-02-08
CA3199760A1 (en) 2022-06-02
JP2023553354A (ja) 2023-12-21
AU2021387993A1 (en) 2023-06-08
US20230381169A1 (en) 2023-11-30
EP4251158A1 (en) 2023-10-04
KR20230112622A (ko) 2023-07-27
WO2022115526A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2024014184A (es) Metodos novedosos
US8067443B2 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
WO2007112352A3 (en) Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
MX2010003375A (es) Derivados de 1h-indol-3-carboxilato de quinuclidin-4-ilmetilo como ligandos del receptor de acetilcolina alfa 7 nicotinico para el tratamiento de enfermedad de alzheimer.
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2007112345A8 (en) Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
WO2010129864A3 (en) Methods and compositions for studying, imaging, and treating pain
PH12014502584A1 (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
NZ598716A (en) Novel enteric combination therapy
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
EP3708168A3 (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
MX2010003556A (es) Regimen de tratamiento para trastornos proliferantes.
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
EP1393722A3 (en) Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
CN111343981A (zh) 使用川地匹坦治疗胃肠疾病的方法
Opler et al. Pharmacotherapy of cognitive deficits in schizophrenia
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
Yue et al. Gut-sourced vasoactive intestinal polypeptide induced by the activation of α7 nicotinic acetylcholine receptor substantially contributes to the anti-inflammatory effect of sinomenine in collagen-induced arthritis
PH12021552266A1 (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Maggi et al. Nitric oxide is the mediator of tachykinin NK3 receptor-induced relaxation in the circular muscle of the guinea-pig ileum
MX2023005895A (es) Tratamiento de la ansiedad al hablar en publico con un agonista del receptor nicotinico alfa 7 de la acetilcolina.
PH12021550741A1 (en) Vibegron for the treatment of overactive bladder symptoms
WO2011132084A3 (en) Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
Jung et al. Effects of lidocaine, ketamine, and remifentanil on withdrawal response of rocuronium